(ILMN) Illumina - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4523271090
Stock: Genetic Analysis, Sequencing, Instruments, Reagents, Kits
Total Rating 72
Risk 89
Buy Signal 0.16
| Risk 5d forecast | |
|---|---|
| Volatility | 42.9% |
| Relative Tail Risk | -6.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.86 |
| Alpha | 20.40 |
| Character TTM | |
|---|---|
| Beta | 1.011 |
| Beta Downside | 0.854 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.94% |
| CAGR/Max DD | -0.26 |
EPS (Earnings per Share)
Revenue
Description: ILMN Illumina March 04, 2026
Illumina, Inc. (ILMN) provides genetic and genomic analysis solutions. These solutions include sequencing and array-based instruments and consumables, such as reagents and whole-genome sequencing kits.
The company also offers various services, including whole-genome sequencing and noninvasive prenatal testing. Genomics is a rapidly advancing field with applications across healthcare and research.
Illumina serves a diverse customer base, including research centers, hospitals, and pharmaceutical companies. Its business model relies on both direct sales and distribution through life-science distributors. The life sciences tools and services sector is characterized by continuous innovation and high capital expenditure.
To gain a deeper understanding of Illuminas market position and financial health, further research on platforms like ValueRay is recommended.
Headlines to watch out for
- Sequencing instrument sales drive capital expenditure
- Consumable recurring revenue fuels growth
- Research and clinical demand dictates sales volume
- Regulatory approvals impact diagnostic market access
- Competition in sequencing technology affects market share
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 850.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.88 > 1.0 |
| NWC/Revenue: 39.24% < 20% (prev 27.42%; Δ 11.82% < -1%) |
| CFO/TA 0.16 > 3% & CFO 1.08b > Net Income 850.0m |
| Net Debt (1.14b) to EBITDA (1.46b): 0.78 < 3 |
| Current Ratio: 2.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (154.0m) vs 12m ago -3.75% < -2% |
| Gross Margin: 66.49% > 18% (prev 0.65%; Δ 6.58k% > 0.5%) |
| Asset Turnover: 67.07% > 50% (prev 69.36%; Δ -2.29% > 0%) |
| Interest Coverage Ratio: 9.41 > 6 (EBITDA TTM 1.46b / Interest Expense TTM 126.0m) |
Altman Z'' 2.61
| A: 0.26 (Total Current Assets 3.29b - Total Current Liabilities 1.58b) / Total Assets 6.64b |
| B: -0.06 (Retained Earnings -392.0m / Total Assets 6.64b) |
| C: 0.18 (EBIT TTM 1.19b / Avg Total Assets 6.47b) |
| D: -0.10 (Book Value of Equity -400.0m / Total Liabilities 3.92b) |
| Altman-Z'' Score: 2.61 = A |
Beneish M -3.02
| DSRI: 1.15 (Receivables 854.0m/751.0m, Revenue 4.34b/4.37b) |
| GMI: 0.98 (GM 66.49% / 65.44%) |
| AQI: 0.91 (AQ_t 0.34 / AQ_t-1 0.37) |
| SGI: 0.99 (Revenue 4.34b / 4.37b) |
| TATA: -0.03 (NI 850.0m - CFO 1.08b) / TA 6.64b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of ILMN shares?
As of March 19, 2026, the stock is trading at USD 120.84 with a total of 1,430,281 shares traded.
Over the past week, the price has changed by +1.19%, over one month by +2.38%, over three months by -5.79% and over the past year by +44.38%.
Over the past week, the price has changed by +1.19%, over one month by +2.38%, over three months by -5.79% and over the past year by +44.38%.
Is ILMN a buy, sell or hold?
Illumina has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold ILMN.
- StrongBuy: 7
- Buy: 5
- Hold: 11
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the ILMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 136.1 | 12.6% |
| Analysts Target Price | 136.1 | 12.6% |
ILMN Fundamental Data Overview March 16, 2026
P/E Trailing = 21.8239
P/E Forward = 23.2019
P/S = 4.1874
P/B = 6.6786
P/EG = 2.1668
Revenue TTM = 4.34b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 577.0m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.14b USD (from netDebt column, last quarter)
Enterprise Value = 19.32b USD (18.19b + Debt 2.55b - CCE 1.42b)
Interest Coverage Ratio = 9.41 (Ebit TTM 1.19b / Interest Expense TTM 126.0m)
EV/FCF = 20.58x (Enterprise Value 19.32b / FCF TTM 939.0m)
FCF Yield = 4.86% (FCF TTM 939.0m / Enterprise Value 19.32b)
FCF Margin = 21.63% (FCF TTM 939.0m / Revenue TTM 4.34b)
Net Margin = 19.58% (Net Income TTM 850.0m / Revenue TTM 4.34b)
Gross Margin = 66.49% ((Revenue TTM 4.34b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 67.59%)
Tobins Q-Ratio = 2.91 (Enterprise Value 19.32b / Total Assets 6.64b)
Interest Expense / Debt = 1.02% (Interest Expense 26.0m / Debt 2.55b)
Taxrate = 11.64% (44.0m / 378.0m)
NOPAT = 1.05b (EBIT 1.19b * (1 - 11.64%))
Current Ratio = 2.08 (Total Current Assets 3.29b / Total Current Liabilities 1.58b)
Debt / Equity = 0.94 (Debt 2.55b / totalStockholderEquity, last quarter 2.72b)
Debt / EBITDA = 0.78 (Net Debt 1.14b / EBITDA 1.46b)
Debt / FCF = 1.21 (Net Debt 1.14b / FCF TTM 939.0m)
Total Stockholder Equity = 2.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.13% (Net Income 850.0m / Total Assets 6.64b)
RoE = 34.94% (Net Income TTM 850.0m / Total Stockholder Equity 2.43b)
RoCE = 30.24% (EBIT 1.19b / Capital Employed (Equity 2.43b + L.T.Debt 1.49b))
RoIC = 23.69% (NOPAT 1.05b / Invested Capital 4.42b)
WACC = 8.56% (E(18.19b)/V(20.74b) * Re(9.64%) + D(2.55b)/V(20.74b) * Rd(1.02%) * (1-Tc(0.12)))
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.58%
[DCF] Terminal Value 79.45% ; FCFF base≈847.0m ; Y1≈1.04b ; Y5≈1.78b
[DCF] Fair Price = 169.0 (EV 26.98b - Net Debt 1.14b = Equity 25.85b / Shares 152.9m; r=8.56% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 48.58 | EPS CAGR: 6.39% | SUE: 0.52 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -1.42% | SUE: 3.20 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.24 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-12-31): EPS=5.12 | Chg7d=-0.007 | Chg30d=-0.011 | Revisions Net=+8 | Growth EPS=+5.8% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=5.84 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+4 | Growth EPS=+14.0% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.1% (Discount Rate 9.6% - Earnings Yield 4.6%)
[Growth] Growth Spread = -0.7% (Analyst 4.4% - Implied 5.1%)
P/E Forward = 23.2019
P/S = 4.1874
P/B = 6.6786
P/EG = 2.1668
Revenue TTM = 4.34b USD
EBIT TTM = 1.19b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 577.0m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.14b USD (from netDebt column, last quarter)
Enterprise Value = 19.32b USD (18.19b + Debt 2.55b - CCE 1.42b)
Interest Coverage Ratio = 9.41 (Ebit TTM 1.19b / Interest Expense TTM 126.0m)
EV/FCF = 20.58x (Enterprise Value 19.32b / FCF TTM 939.0m)
FCF Yield = 4.86% (FCF TTM 939.0m / Enterprise Value 19.32b)
FCF Margin = 21.63% (FCF TTM 939.0m / Revenue TTM 4.34b)
Net Margin = 19.58% (Net Income TTM 850.0m / Revenue TTM 4.34b)
Gross Margin = 66.49% ((Revenue TTM 4.34b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 67.59%)
Tobins Q-Ratio = 2.91 (Enterprise Value 19.32b / Total Assets 6.64b)
Interest Expense / Debt = 1.02% (Interest Expense 26.0m / Debt 2.55b)
Taxrate = 11.64% (44.0m / 378.0m)
NOPAT = 1.05b (EBIT 1.19b * (1 - 11.64%))
Current Ratio = 2.08 (Total Current Assets 3.29b / Total Current Liabilities 1.58b)
Debt / Equity = 0.94 (Debt 2.55b / totalStockholderEquity, last quarter 2.72b)
Debt / EBITDA = 0.78 (Net Debt 1.14b / EBITDA 1.46b)
Debt / FCF = 1.21 (Net Debt 1.14b / FCF TTM 939.0m)
Total Stockholder Equity = 2.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.13% (Net Income 850.0m / Total Assets 6.64b)
RoE = 34.94% (Net Income TTM 850.0m / Total Stockholder Equity 2.43b)
RoCE = 30.24% (EBIT 1.19b / Capital Employed (Equity 2.43b + L.T.Debt 1.49b))
RoIC = 23.69% (NOPAT 1.05b / Invested Capital 4.42b)
WACC = 8.56% (E(18.19b)/V(20.74b) * Re(9.64%) + D(2.55b)/V(20.74b) * Rd(1.02%) * (1-Tc(0.12)))
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.58%
[DCF] Terminal Value 79.45% ; FCFF base≈847.0m ; Y1≈1.04b ; Y5≈1.78b
[DCF] Fair Price = 169.0 (EV 26.98b - Net Debt 1.14b = Equity 25.85b / Shares 152.9m; r=8.56% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 48.58 | EPS CAGR: 6.39% | SUE: 0.52 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -1.42% | SUE: 3.20 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.24 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-12-31): EPS=5.12 | Chg7d=-0.007 | Chg30d=-0.011 | Revisions Net=+8 | Growth EPS=+5.8% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=5.84 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+4 | Growth EPS=+14.0% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.1% (Discount Rate 9.6% - Earnings Yield 4.6%)
[Growth] Growth Spread = -0.7% (Analyst 4.4% - Implied 5.1%)